ESTABLISHMENT LABS INC (ESTA)
Health Care · Medical Devices (Aesthetics) · NASDAQ
Establishment Labs is a medical technology company advancing women's health through its next-generation Motiva breast implant technology and aesthetic surgical solutions.
What ESTABLISHMENT LABS INC does
Establishment Labs is a medical technology company focused on women’s health, specifically within the breast aesthetics and reconstructive surgery market. The company develops and markets a portfolio of innovative breast implants, including its flagship Motiva Implants line, alongside other related surgical technologies and planning software.
Themes: women's health, aesthetic surgery, breast implants, medtech
Fundamentals
- Price$60.61 as of 2026-10-08 close
- Market cap$1.8B as of 2026-08-06 (share count; price 2026-10-08)
- 1-year return+51.1% 2025-10-08 close $40.12 → 2026-10-08 close $60.61
- P/En/a negative earnings
- Net margin-24.2% FY2025, SEC XBRL
- Gross margin+69.3% FY2025, SEC XBRL
- ROE-216.9% FY2025, SEC XBRL
- Debt / equity17.58 as of 2026-09-03
- Revenue growth (YoY)+34.9% as of 2026-09-03
- Revenue CAGR (3y)+9.3% SEC XBRL
- Beta1.74 as of 2026-09-03
- Last reported earnings2026-08-06 SEC EDGAR Form 8-K (Item 2.02)
How ESTA compares in its sector
- net profit marginmiddle range 430 covered Health Care peers, as of 2026-09-03
- operating marginmiddle range 417 covered Health Care peers, as of 2026-09-03
- gross marginmiddle range 189 covered Health Care peers, as of 2026-09-03
- return on equitybottom 10% 510 covered Health Care peers, as of 2026-09-03
- 3-year revenue CAGRmiddle range 402 covered Health Care peers
- free cash flow (absolute dollars, latest fiscal year)middle range 494 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
How ESTABLISHMENT LABS INC looks technically
ESTABLISHMENT LABS INC (ESTA) is trading 16.9% below its 200-day average, the long-term trend line — a long-term downtrend. Its 50-day average crossed above its 200-day average about 305 trading days ago — a "golden cross", a bullish long-term signal. A strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 35, with sellers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 31, neither overbought (above 70) nor oversold (below 30). MACD, a trend-momentum gauge, turned bearish about 1 trading day ago (its momentum flipped negative). It just made a new 20-day low, its first since 2026-04-10, breaking below its recent trading range. It is 37.9% below its highest point of the past year.
Trend
8
| Distance from the 200-day | it is trading 16.9% below its 200-day average, the long-term trend line — a long-term downtrend | -16.9% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $73.03 | $73.03 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $72.98 | $72.98 |
| Swing structure | each recent peak has been lower than the one before it and each dip deeper — the pattern chart-watchers call a downtrend, which describes where price has already been and not where it goes next | lower highs and lower lows |
| Last swing turn | its last significant turn was a swing high 35 calendar days ago — the swings before that are what the structure reading is measured on | 35 sessions |
| Wave structure | its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes above 76.42. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible downward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 305 trading days ago — a "golden cross", a bullish long-term signal | 305 sessions |
| Trend strength (14-day ADX) | a strong downtrend is in place — ADX, a 0–100 trend-strength gauge, is 35, with sellers in control | 34.7 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 31, neither overbought (above 70) nor oversold (below 30) | 31.4 |
|---|---|---|
| Position in its 14-day range | it is trading near the bottom of its 14-day range ($59.81 to $71.61) — its "stochastic" reading is 7 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been slipping within that range over the last few sessions. | 6.8 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, turned bearish about 1 trading day ago (its momentum flipped negative) | 1 session |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $97.59 | $97.59 |
|---|---|---|
| From the 52-week high | it is 37.9% below its 52-week high (its highest price of the past year) | -37.9% |
| Above the 52-week low | it is 57.9% above its 52-week low (its lowest price of the past year) | +57.9% |
| Below the 52-week high | it is 37.9% below its highest point of the past year | 37.9% |
| Since a 20-day breakout | it just made a new 20-day low, its first since 2026-04-10, breaking below its recent trading range | 1 session |
| Since a 55-day breakout | it just made a new 55-day low, its first since 2026-04-10, breaking below its recent trading range | 1 session |
| All-time high | its highest closing price on record is $97.59 (set on 2026-08-03) | $97.59 |
| Given back of the 52-week move | over the past year its closes ranged ($38.94 to $95.65), and it has given back a bit over half of its rise from last year’s low — 62% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $58.79 to $60.60. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 61.8% |
| From the all-time high | it is 37.9% below its all-time high | -37.9% |
| Nearest price level | it is trading 1.4% below a resistance level at $61.47 — a price it turned at twice since 2025-11-18, most recently on 2026-04-29. Since 2024-10-08 it has 9 such levels below the current price and 9 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | +1.4% |
| All-time low | its lowest closing price on record is $7.56 (set on 2020-03-18) | $7.56 |
| Above the all-time low | it is 701.7% above its all-time low | +701.7% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are about average versus its own recent 6-month history | 52nd percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $2.96 between its high and its low — about 4.9% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $2.96 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $60.53 and $73.29 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $60.53 – $66.91 – $73.29 |
| Typical daily range (% of price) | its price moves about 4.9% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 4.9% |
| Stretch from the 200-day average | it is trading 4.2 daily ranges below its 200-day average price (17.0% below it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 4.2 daily ranges below its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 1.61× |
|---|
Analyst
2
| Change in the average price target | analysts' average price target is unchanged from the prior reading | 0.0% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
1
| Since a doji | 1 session ago it opened and closed at almost the same price after trading through a wider range — a "doji", the classic picture of buyers and sellers finishing the session level | 1 session ago |
|---|
Price gaps
2
| Gap at the open | it opened on 2026-10-08 0.7% below the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | -0.7% |
|---|---|---|
| Gap filled | a 2.1% gap up opened on 2026-09-17 has been "filled" 15 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 15 sessions ago |
Price streaks
1
| Closing streak | it has closed lower 3 sessions in a row, a -8.82% move over the run — an unbroken run of down days, which describes what has already happened and says nothing about the next session | 3 sessions down |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock lagged the market by 20.5 percentage points (the stock lost 19.5% while the market gained 1.0%) | -20.5% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock lagged the market by 34.9 percentage points (the stock lost 31.1% while the market gained 3.8%) | -34.9% |
| vs market, 6 months | over the past 6 months this stock lagged the market by 17.0 percentage points (the stock gained 0.5% while the market gained 17.5%) | -17.0% |
| vs market, 12 months | over the past 12 months this stock beat the market by 36.1 percentage points (the stock gained 51.1% while the market gained 15.0%) | +36.1% |
Signal agreement
2
| Bullish technical signals | 2 of the 9 technical signals we can compute for it are currently in a bullish state: a "golden cross" — its 50-day average is above its 200-day, near the bottom of its 14-day range (oversold) — these describe past price behaviour, not a forecast | 2 of 9 |
|---|---|---|
| Bearish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bearish state: trading below its 200-day average, a fresh 20-day low, MACD momentum is negative, a strong downtrend, with sellers in control, lagging the market over 6 months, trading below the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 21% below the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-09-01 and projected forward over today's price, the side traders read as an established downtrend, with the band above acting as the level that would have to be cleared. The band itself is thick, spanning 9.1% of the share price, which is taken to mean a barrier that has held for a while and takes effort to cross. | -21.1% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 19% below the average price paid so far this year, so the typical buyer over that stretch is under water. That average is $74.51 — a volume-weighted average of daily closes over 190 sessions, not a true tick-by-tick VWAP. | -18.7% |
|---|---|---|
| Vs the average paid since it last reported | the price is 15% below the average price paid since it last reported on 2026-08-06 (its 8-K), so the typical buyer over that stretch is under water. That average is $71.39 — a volume-weighted average of daily closes over 45 sessions, not a true tick-by-tick VWAP. | -15.1% |
Price levels it has turned at before
ESTA last closed at $60.61 on 2026-10-08. Since 2024-10-08 it has turned at 9 prices below its last close and 9 above; the 3 nearest below and the 3 nearest above are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $61.47 | Resistance | 1.4% above the last close | turned there twice · 2025-11-18 to 2026-04-29 |
| $63.18 | Resistance | 4.2% above the last close | turned there three times · 2025-12-03 to 2026-01-27 |
| $64.62 | Resistance | 6.6% above the last close | turned there twice · 2026-02-24 to 2026-05-15 |
| $47.22 | Support | 22.1% below the last close | turned there six times · 2024-12-02 to 2025-11-03 |
| $44.68 | Support | 26.3% below the last close | turned there twice · 2025-07-24 to 2025-08-05 |
| $42.82 | Support | 29.4% below the last close | turned there four times · 2024-10-31 to 2025-10-02 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part downward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes above $76.42.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $53.43 and $62.21 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close above $76.42.
This reading has stood for 20 trading days, since 2026-09-11.
Read from daily closes as of 2026-10-08.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading below the 200-day moving average · Pulled back from the 12-month high · Broke down to a new 20-day low · MACD just crossed bearish (12/26/9) · lagging the market · At the bottom of its 14-day range (stochastic below 20) | Learn: moving average · golden cross · adx · rsi · macd · breakout · fifty two week high low
Based on daily closing prices as of 2026-10-08. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.22 mean, 1=Strong Buy…5=Strong Sell) — 9 analysts
- Mean price target$102.44 range $92.00 – $117.00; median $105.00
Analyst estimates, as of 2026-10-08. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for ESTA
- Consensus EPS estimate-$0.23 next reporting period, as of 2026-10-08
- Estimate change, 30 days$0.00 from -$0.23, on 2026-09-03, 35-day window
- Readings revised upward13% of 8 comparable readings
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["History of operating losses and uncertainty regarding achieving/maintaining profitability.","Dependency on the commercial success of the Motiva Implants product line.","Significant regulatory risks and potential for supply chain disruptions from single-source suppliers."]
What changed in the latest 10-Q
AI-assisted comparison of ESTA's 10-Q filed 2026-08-07 against the prior one filed 2026-05-08.
Management's Discussion & Analysis (MD&A)
- Added:
- Newer filing (2026-08-07) adds: On June 29, 2026, the Company announced the appointment of Taylor Harris to its Board of Directors.
- Newer filing (2026-08-07) adds: On June 25, 2026, the Company was added as a member of the U.S. small-cap Russell 2000 Index as part of the 2026 Russell indexes reconstitution.
- Newer filing (2026-08-07) presents results for the three and six months ended June 30, 2026 and 2025, including revenue of $67,542 and $127,419 (in thousands) for the respective 2026 periods.
- Newer filing (2026-08-07) includes a six-month net loss of $25,130 (in thousands) and loss before income taxes of $24,836 (in thousands) for the six months ended June 30, 2026.
- Newer filing (2026-08-07) states cash balance as of June 30, 2026 was $71.2 million and accumulated deficit of $520.9 million.
- Removed:
- Older filing (2026-05-08) includes a detailed introductory paragraph under Critical Accounting Policies explaining the basis of preparation of consolidated financial statements in accordance with GAAP and general discussion of estimates and judgments; this paragraph is absent from the newer filing.
- Older filing (2026-05-08) presents results for the three months ended March 31, 2026 and 2025, including revenue of $59,877 and $41,377 (in thousands), net loss of $13,382 and $20,710 (in thousands), and cash balance of $68.1 million and accumulated deficit of $509.1 million as of March 31, 2026; these figures are not repeated in the newer filing.
- Older filing (2026-05-08) refers to Note 16 'Subsequent Events' for additional information on the Amended Credit Agreement; the newer filing refers to Note 4 'Debt' instead.
- Reworded:
- Newer filing (2026-08-07) describes the February 24, 2026 leadership change as the appointment of Cassandra 'Sandra' Harris to succeed Raj Denhoy as CFO; older filing (2026-05-08) describes it as a strategic leadership transition of Raj Denhoy to Senior Vice President, Global Strategy, and the appointment of Harris as CFO.
- Newer filing (2026-08-07) states financial highlights for the six months ended June 30, 2026 with revenue of $127.4 million vs $92.7 million, an increase of $34.7 million (37.5%); older filing (2026-05-08) states financial highlights for the three months ended March 31, 2026 with revenue of $59.9 million vs $41.4 million, an increase of $18.5 million (44.7%).
- Newer filing (2026-08-07) reports Amended Credit Agreement was entered into 'On April 30, 2026, the Company entered into'; older filing (2026-05-08) reports 'On April 30, 2026, we entered into' - minor pronoun change from 'the Company' to 'we'.
- Newer filing (2026-08-07) states Critical Accounting Policies section says policies were disclosed in 'the Annual Report on Form 10-K'; older filing (2026-05-08) refers to 'the Form 10-K' in the final sentence.
- Newer filing (2026-08-07) comparison for the three months ended June 30, 2026 discusses revenue increase of $16.2 million (31.7%) to $67.5 million, attributed to $14.4 million increase in U.S. sales and $1.8 million increase outside the U.S.; older filing (2026-05-08) discusses three months ended March 31, 2026 revenue increase of $18.5 million (44.7%), attributed to $13.5 million increase in U.S. sales and $5.0 million increase outside the U.S. primarily in Asia-Pacific and Latin America.
- Newer filing (2026-08-07) reports gross margin of 70.6% for Q2 2026 vs 68.8% for Q2 2025, attributed to more favorable geographic sales mix, higher U.S. selling prices, direct market expansion outside the U.S., and increased revenue from minimally invasive product portfolio partially offset by inventory obsolescence reserve; older filing (2026-05-08) reports gross margin of 70.7% for Q1 2026 vs 67.2% for Q1 2025, attributed to favorable U.S. sales impact due to higher selling prices partially offset by inventory obsolescence reserve.
- Newer filing (2026-08-07) SG&A discussion for Q2 2026 cites increases in professional fees associated with the Amended Credit Agreement ($1.9M), consulting fees ($0.9M), sales commissions ($0.9M) partially offset by decrease in sales and marketing expense ($2.0M); older filing (2026-05-08) SG&A discussion for Q1 2026 cites increases in personnel and consulting costs and freight partially offset by decreases in bad debt expense and sales and marketing expenses.
- Newer filing (2026-08-07) interest expense discussion for Q2 2026 states increase primarily due to increase in debt associated with the Amended Credit Agreement; older filing (2026-05-08) does not provide a comparable interest expense discussion in the visible excerpt.
- Notes:
- The newer filing text is truncated at 'Provision for income taxes decreased $1.0 million, or 99.4%, to $6' and does not include the full remainder of the MD&A section.
- The older filing text is truncated at 'R&D expense remained relatively consistent at $5.2 million for the three months ended March 31' and does not include the full remainder of the MD&A section.
- Only MD&A sections provided in the prompt were compared; other sections of the filings were not available for review.
Risk Factors
- Added:
- Newer filing (2026-08-07) discloses that on May 27, 2026, Edward J. Schutter, a Board member, adopted a Rule 10b5-1 trading plan for up to 15,000 common shares, with sales starting August 25, 2026 and plan expiration on December 31, 2026 or when all shares are sold.
- Newer filing (2026-08-07) discloses that on June 12, 2026, Bryan Slotkin, a Board member, adopted a Rule 10b5-1 trading plan for up to 13,422 common shares, with sales starting September 14, 2026 and plan expiration on May 21, 2027 or when all shares are sold.
- Newer filing (2026-08-07) adds '25' and 'Table of Contents' page markers in Item 4 area.
- Newer filing (2026-08-07) includes exhibit 10.1 Credit Agreement and Guaranty dated April 30, 2026, incorporated by reference from Exhibit 10.1 to Form 8-K filed April 30, 2026.
- Newer filing (2026-08-07) adds page markers '26', '27', and '28' with Table of Contents references.
- Removed:
- Older filing (2026-05-08) disclosed that on March 6, 2026, Nicholas Lewin, chairman of the Board, adopted a Rule 10b5-1 trading plan for up to 100,000 common shares, with sales starting June 8, 2026 at a $101 per share threshold and plan expiration on November 30, 2026 or when all shares are sold.
- Older filing (2026-05-08) included exhibit 10.1 Employment Agreement between Registrant and Cassandra Harris, dated February 23, 2026, incorporated by reference from Exhibit 10.24 to Form 10-K filed February 27, 2026.
- Older filing (2026-05-08) included exhibit 10.2 Credit Agreement and Guaranty dated April 30, 2026, incorporated by reference from Exhibit 10.1 to Form 8-K filed April 30, 2026.
- Older filing (2026-05-08) included page markers '45', '46', and '47'.
- Reworded:
- Insider Trading Arrangements section: newer filing (2026-08-07) replaces the Nicholas Lewin plan disclosure with Edward J. Schutter and Bryan Slotkin plan disclosures; older filing (2026-05-08) had only the Nicholas Lewin plan.
- Exhibit numbering shifted: the Credit Agreement and Guaranty is exhibit 10.1 in the newer filing (2026-08-07) but was exhibit 10.2 in the older filing (2026-05-08), due to removal of the Cassandra Harris Employment Agreement exhibit.
- The 10b5-1 plan disclosures in the newer filing omit the specific per-share price threshold (e.g., '$101 per share') that appeared in the older filing's Nicholas Lewin disclosure.
- Notes:
- The extracted 'Risk Factors' sections contain surrounding items (Items 2-6 and signatures) rather than only Item 1A; comparison reflects all provided text.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
No open-market insider purchases or sales recorded in the last 90 days, of which we have read Form 4 filings through 2026-10-05. The 4 days since 2026-10-05 have not been checked yet.
- Last 180 days · read to 2026-10-050 buys · 22 sells ($33M) — 2 selling insiders
Most recent open-market transaction: 2026-05-28. Based on Form 4 filings read through 2026-10-05; anything filed since is not yet included.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about ESTA's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Short interest (FINRA)
ESTA had 4,386,350 shares of reported short interest as of the 2026-09-15 FINRA settlement date (delayed, bi-monthly; not real-time).
ESTA had 14.7% of its shares outstanding sold short as of the 2026-09-15 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 12.76 days to cover at the same settlement.
- Reported short interest (shares) 4,386,350
- Short interest (% of shares outstanding) 14.7%
- Prior settlement (shares) 4,396,568
- Reported change -0.23%
- Days to cover (reported) 12.76
Reported to FINRA as of the 2026-09-15 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare ESTA vs…
Frequently asked questions
What does ESTABLISHMENT LABS INC (ESTA) do?
Establishment Labs is a medical technology company focused on women’s health, specifically within the breast aesthetics and reconstructive surgery market. The company develops and markets a portfolio of innovative breast implants, including its flagship Motiva Implants line, alongside other related surgical technologies and planning software.
What sector is ESTABLISHMENT LABS INC (ESTA) in?
ESTABLISHMENT LABS INC (ESTA) is classified in the Health Care sector. Its industry is Medical Devices (Aesthetics). It trades on NASDAQ.
Who are ESTABLISHMENT LABS INC's (ESTA) competitors?
Notable peers of ESTABLISHMENT LABS INC (ESTA) include Johnson & Johnson (Mentor), AbbVie (Allergan Aesthetics) and Sientra. This peer set is informational only — not financial advice.
Is ESTABLISHMENT LABS INC (ESTA) overbought or oversold right now?
ESTABLISHMENT LABS INC (ESTA) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 31, in the neutral middle (as of 2026-10-08). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on ESTA come from?
Fundamentals come from SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest; prices are market data, as of 2026-09-03; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-08.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.